Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Finance Watch: Two New VC Funds Raise $500m; One New US IPO; And Galena's 'Strategic Review'

Executive Summary

Pivotal and Biomatics launch new VC funds totaling $300m and $200m, respectively; Spero raises a $51.7m Series C round; BeyondSpring is March's only US IPO, so far; Aurinia and TG Therapeutics capitalize on positive data with secondary offerings; and Galena hires a "strategic review" advisor.

Advertisement

Related Content

Vacant Post-Lung Transplant Market Is Big Opportunity For Breath Therapeutics
TG Celebrates High Risk CLL Data - But Cloud Looms From Rival Trial
New AURA Lupus Data Bode Well For Aurinia's Voclosporin In Future Phase III
Tocagen Aims Double Barrels At Glioma
VC Roundup: Infectious Disease Startup Snags $150m And Former Biogen CEO Scangos
VC Roundup: Early-Stage Funding Slips Again In Third Quarter, Plus 15 New Financings
Galena Left To Hope Review Of Trial Operations Rescues NeuVax
Early February VC Tally: 6 Biotech Firms Raise $153.5m
FINANCE ROUNDUP: VC Investment Not Hurt Yet By Biotech Stock Slump
Venture cash piling on to beat 1Q total

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC098417

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel